Supplementary Tables S1 and S2 from FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer
crossref(2023)
摘要
Supplementary Table 1 shows adverse reactions occurring at a frequency of 10% or higher in patients with SCLC who received lurbinectedin in Study B-005. Supplementary Table 2 shows select laboratory abnormalities as worsening from baseline and occurring at a rate of 20% or higher in patients with SCLC who received lurbinectedin in Study B-005.
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要